While the overall risk of secondary cancers after Kaposi sarcoma has declined in people with HIV/AIDS, clinicians should be aware that certain cancers are becoming increasingly common in the highly active antiretroviral therapy era compared with the pre-HAART era. READ MORE

Conferences

Health-related quality of life and its impact on disease progression should be a consideration when selecting treatment for sarcoma.

READ MORE

J Code Updates

News

While the overall risk of secondary cancers after Kaposi sarcoma has declined in people with HIV/AIDS, clinicians should be aware that certain cancers are becoming increasingly common in the highly active antiretroviral therapy era compared with the pre-HAART era.

READ MORE

Differences in the immunologic profiles of soft tissue sarcoma subtypes could have implications for treatment with immune checkpoint inhibitors.

READ MORE

The American Society of Clinical Oncology released new recommendations for managing patients with clinically localized small renal masses.

READ MORE

Childhood survivors of bone cancer and soft-tissue sarcoma face increased risk of hospitalization for years after initial diagnosis.

READ MORE

Research in Review

The best potential strategy involving tyrosine kinase inhibitors for the treatment of gastrointestinal stromal tumors has been identified.

READ MORE

Kaposi Sarcoma (KS) skin lesions are more likely to respond to local external beam radiotherapy than repeat radiotherapy.

READ MORE

Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors, supporting efforts for further research.

READ MORE

Neoadjuvant chemotherapy with epirubicin plus ifosfamide improves outcomes in patients with soft tissue sarcoma who are at high-risk of recurrence.

READ MORE